New Chimeric Antigen Receptor Design for Solid Tumors

In recent years, chimeric antigen receptor (CAR) T-cell therapy has become popular in immunotherapy, particularly after its tremendous success in the treatment of lineage-restricted hematologic cancers. However, the application of CAR T-cell therapy for solid tumors has not reached its full potentia...

Full description

Bibliographic Details
Main Authors: Yuedi Wang, Feifei Luo, Jiao Yang, Chujun Zhao, Yiwei Chu
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-12-01
Series:Frontiers in Immunology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.01934/full
id doaj-a6fffad037cc455f888f9f4806725d06
record_format Article
spelling doaj-a6fffad037cc455f888f9f4806725d062020-11-24T22:38:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-12-01810.3389/fimmu.2017.01934306985New Chimeric Antigen Receptor Design for Solid TumorsYuedi Wang0Yuedi Wang1Feifei Luo2Feifei Luo3Jiao Yang4Jiao Yang5Chujun Zhao6Yiwei Chu7Yiwei Chu8Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, ChinaBiotherapy Research Center, Fudan University, Shanghai, ChinaBiotherapy Research Center, Fudan University, Shanghai, ChinaDepartment of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, ChinaBiotherapy Research Center, Fudan University, Shanghai, ChinaNorthfield Mount Hermon School, Mount Hermon, MA, United StatesDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, ChinaBiotherapy Research Center, Fudan University, Shanghai, ChinaIn recent years, chimeric antigen receptor (CAR) T-cell therapy has become popular in immunotherapy, particularly after its tremendous success in the treatment of lineage-restricted hematologic cancers. However, the application of CAR T-cell therapy for solid tumors has not reached its full potential because of the lack of specific tumor antigens and inhibitory factors in suppressive tumor microenvironment (TME) (e.g., programmed death ligand-1, myeloid-derived suppressor cells, and transforming growth factor-β). In this review, we include some limitations in CAR design, such as tumor heterogeneity, indefinite spatial distance between CAR T-cell and its target cell, and suppressive TME. We also summarize some new approaches to overcome these hurdles, including targeting neoantigens and/or multiple antigens at once and depleting some inhibitory factors.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01934/fullchimeric antigen receptor T-cellimmunotherapysolid tumoradoptive T-cell therapytumor microenvironment
collection DOAJ
language English
format Article
sources DOAJ
author Yuedi Wang
Yuedi Wang
Feifei Luo
Feifei Luo
Jiao Yang
Jiao Yang
Chujun Zhao
Yiwei Chu
Yiwei Chu
spellingShingle Yuedi Wang
Yuedi Wang
Feifei Luo
Feifei Luo
Jiao Yang
Jiao Yang
Chujun Zhao
Yiwei Chu
Yiwei Chu
New Chimeric Antigen Receptor Design for Solid Tumors
Frontiers in Immunology
chimeric antigen receptor T-cell
immunotherapy
solid tumor
adoptive T-cell therapy
tumor microenvironment
author_facet Yuedi Wang
Yuedi Wang
Feifei Luo
Feifei Luo
Jiao Yang
Jiao Yang
Chujun Zhao
Yiwei Chu
Yiwei Chu
author_sort Yuedi Wang
title New Chimeric Antigen Receptor Design for Solid Tumors
title_short New Chimeric Antigen Receptor Design for Solid Tumors
title_full New Chimeric Antigen Receptor Design for Solid Tumors
title_fullStr New Chimeric Antigen Receptor Design for Solid Tumors
title_full_unstemmed New Chimeric Antigen Receptor Design for Solid Tumors
title_sort new chimeric antigen receptor design for solid tumors
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2017-12-01
description In recent years, chimeric antigen receptor (CAR) T-cell therapy has become popular in immunotherapy, particularly after its tremendous success in the treatment of lineage-restricted hematologic cancers. However, the application of CAR T-cell therapy for solid tumors has not reached its full potential because of the lack of specific tumor antigens and inhibitory factors in suppressive tumor microenvironment (TME) (e.g., programmed death ligand-1, myeloid-derived suppressor cells, and transforming growth factor-β). In this review, we include some limitations in CAR design, such as tumor heterogeneity, indefinite spatial distance between CAR T-cell and its target cell, and suppressive TME. We also summarize some new approaches to overcome these hurdles, including targeting neoantigens and/or multiple antigens at once and depleting some inhibitory factors.
topic chimeric antigen receptor T-cell
immunotherapy
solid tumor
adoptive T-cell therapy
tumor microenvironment
url http://journal.frontiersin.org/article/10.3389/fimmu.2017.01934/full
work_keys_str_mv AT yuediwang newchimericantigenreceptordesignforsolidtumors
AT yuediwang newchimericantigenreceptordesignforsolidtumors
AT feifeiluo newchimericantigenreceptordesignforsolidtumors
AT feifeiluo newchimericantigenreceptordesignforsolidtumors
AT jiaoyang newchimericantigenreceptordesignforsolidtumors
AT jiaoyang newchimericantigenreceptordesignforsolidtumors
AT chujunzhao newchimericantigenreceptordesignforsolidtumors
AT yiweichu newchimericantigenreceptordesignforsolidtumors
AT yiweichu newchimericantigenreceptordesignforsolidtumors
_version_ 1725712071683735552